The study aims to find out if a drug called BHV-7000 is safe and works well for adults with a specific type of epilepsy, called refractory focal onset epilepsy. Refractory means that the epilepsy doesn't get better with usual treatments. Focal onset epilepsy is a kind where seizures start in one part of the brain.
Eligibility: Adults aged 18-75 with this type of epilepsy for at least a year can join. They must have tried at least two anti-seizure medicines without success and be on one to three current medications. Participants need to keep a detailed seizure diary.
Exclusions: People who had severe seizures lasting too long, frequent uncountable seizures, or recent brain surgeries cannot join.
- Duration of participation is not specified, but multiple visits will be needed.
- The study involves taking a new medication, so there may be unknown risks.
- Compensation details are not provided, but participants may receive free medication.
If you think you fit the criteria and are interested, discuss it with your doctor to understand the potential risks and benefits.